Reni J. Benjamin
Stock Analyst at Citizens
(3.67)
# 750
Out of 5,165 analysts
20
Total ratings
38.89%
Success rate
14.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni J. Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LYEL Lyell Immunopharma | Initiates: Market Outperform | $34 | $21.13 | +60.91% | 1 | Mar 9, 2026 | |
| IOVA Iovance Biotherapeutics | Upgrades: Market Outperform | $5 | $4.04 | +23.76% | 2 | Mar 3, 2026 | |
| IMMP Immutep | Initiates: Market Outperform | $10 | $0.47 | +2,049.15% | 2 | Feb 23, 2026 | |
| SMMT Summit Therapeutics | Reiterates: Market Outperform | $40 | $16.18 | +147.30% | 4 | Jan 30, 2026 | |
| BCAX Bicara Therapeutics | Initiates: Market Outperform | $31 | $19.40 | +59.79% | 1 | Jan 29, 2026 | |
| ZYME Zymeworks | Initiates: Market Outperform | $32 | $23.62 | +35.48% | 1 | Dec 3, 2025 | |
| ONC BeOne Medicines AG | Maintains: Market Outperform | $348 → $396 | $289.65 | +36.72% | 1 | Nov 7, 2025 | |
| SANA Sana Biotechnology | Maintains: Market Outperform | $5 → $8 | $3.27 | +144.65% | 1 | Oct 30, 2025 | |
| KURA Kura Oncology | Reiterates: Market Outperform | $24 | $8.73 | +174.91% | 2 | Oct 20, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $69.26 | - | 1 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $3 | $0.81 | +269.91% | 1 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $3 | $3.36 | -10.71% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.18 | - | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $10 | $5.05 | +98.02% | 1 | Aug 12, 2025 |
Lyell Immunopharma
Mar 9, 2026
Initiates: Market Outperform
Price Target: $34
Current: $21.13
Upside: +60.91%
Iovance Biotherapeutics
Mar 3, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $4.04
Upside: +23.76%
Immutep
Feb 23, 2026
Initiates: Market Outperform
Price Target: $10
Current: $0.47
Upside: +2,049.15%
Summit Therapeutics
Jan 30, 2026
Reiterates: Market Outperform
Price Target: $40
Current: $16.18
Upside: +147.30%
Bicara Therapeutics
Jan 29, 2026
Initiates: Market Outperform
Price Target: $31
Current: $19.40
Upside: +59.79%
Zymeworks
Dec 3, 2025
Initiates: Market Outperform
Price Target: $32
Current: $23.62
Upside: +35.48%
BeOne Medicines AG
Nov 7, 2025
Maintains: Market Outperform
Price Target: $348 → $396
Current: $289.65
Upside: +36.72%
Sana Biotechnology
Oct 30, 2025
Maintains: Market Outperform
Price Target: $5 → $8
Current: $3.27
Upside: +144.65%
Kura Oncology
Oct 20, 2025
Reiterates: Market Outperform
Price Target: $24
Current: $8.73
Upside: +174.91%
Inhibrx Biosciences
Aug 22, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $69.26
Upside: -
Aug 21, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $0.81
Upside: +269.91%
Aug 18, 2025
Maintains: Market Outperform
Price Target: $4 → $3
Current: $3.36
Upside: -10.71%
Aug 13, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.18
Upside: -
Aug 12, 2025
Maintains: Market Outperform
Price Target: $22 → $10
Current: $5.05
Upside: +98.02%